Abnormal fundus autofluorescence results of patients in long-term treatment with deferoxamine

Ophthalmology

Volumn 119, Issue 8, 2012, Pages 1693-1700

  Viola, Francesco ^a   Barteselli, Giulio ^a   Dell'Arti, Laura ^a   Vezzola, Diego ^a   Villani, Edoardo ^a   Mapelli, Chiara ^a   Zanaboni, Laura ^a   Cappellini, Maria D ^a   Ratiglia, Roberto ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; FERRITIN;

ADULT; AGED; ARTICLE; AUTOFLUORESCENCE IMAGING; BETA THALASSEMIA; CASE CONTROL STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE COURSE; EYE FUNDUS; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; FUNDUS AUTOFLUORESCENCE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROSPECTIVE STUDY; THALASSEMIA INTERMEDIA; TREATMENT DURATION; VISUAL ACUITY;

ADULT; AGED; BETA-THALASSEMIA; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DEFEROXAMINE; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; MACULA LUTEA; MALE; MIDDLE AGED; OPHTHALMOSCOPY; PHOTOGRAPHY; PROSPECTIVE STUDIES; RETINAL DISEASES; SIDEROPHORES; VISUAL ACUITY; YOUNG ADULT;

EID: 84864484475     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2012.01.039     Document Type: Article

References (30)

1. G.M. Brittenham Iron-chelating therapy for transfusional iron overload N Engl J Med 364 2011 146 156
2. S.C. Davies, R.E. Marcus, J.L. Hungerford Ocular toxicity of high-dose intravenous desferrioxamine Lancet 2 1983 181 184
3. R. Haimovici, J.D. D'Amico, E.S. Gragoudas, S. Sokol Deferoxamine Retinopathy Study Group The expanded clinical spectrum of deferoxamine retinopathy Ophthalmology 109 2002 164 171
4. V. Bansal, I. Elgarbly, F.D. Ghanchi, P.L. Atkinson Bull's eye maculopathy with deferoxamine Eur J Haematol 70 2003 420 421
5. M.G. Marciani, P. Ciaciulli, N. Stefani Toxic effects of high-dose deferoxamine treatment in patients with iron overload: an electrophysiological study of cerebral and visual function Haematologica 76 1991 131 134
6. J.S. Baath, W.C. Lam, M. Kirby, A. Chun Deferoxamine-related ocular toxicity: incidence and outcome in a pediatric population Retina 28 2008 894 899
7. A.H.S. Rahi, J.L. Hungerford, A.I. Ahmed Ocular toxicity of desferrioxamine: light microscopic histochemical and ultrastructural findings Br J Ophthalmol 70 1986 373 381
8. P.A. Good, A. Claxson, C.J. Morris, D.R. Blake A model for desferrioxamine-induced retinopathy using the albino rat Ophthalmologica 201 1990 32 36
9. P.L. Gehlbach, R.L. Purple, P.E. Hallaway, B.E. Hedlund Polymer conjugation reduces deferoxamine induced retinopathy in an albino rat model Invest Ophthalmol Vis Sci 34 1993 2871 2877
10. F.C. Delori, C.K. Dorey, G. Staurenghi In vivo autofluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics Invest Ophthalmol Vis Sci 36 1995 718 729
11. A. von Rückmann, F.W. Fitzke, A.C. Bird Fundus autofluorescence in age-related macular disease imaged with a laser scanning ophthalmoscope Invest Ophthalmol Vis Sci 38 1997 478 486
12. A. von Rückmann, F.W. Fitzke, A.C. Bird In vivo fundus autofluorescence in macular dystrophies Arch Ophthalmol 115 1997 609 615
13. F.G. Holz, C. Bellman, S. Staudt Fundus autofluorescence and development of geographic atrophy in age-related macular degeneration Invest Ophthalmol Vis Sci 42 2001 1051 1056
14. U. Kellner, A.B. Renner, H. Tillack Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/ hydroxychloroquine Invest Ophthalmol Vis Sci 47 2006 3531 3538
15. S. Reddy, D. Iturralde, C. Meyerle Fundus autofluorescence in retinopathy caused by deferoxamine toxicity Retin Cases Brief Rep 1 2007 120 122
16. D.M. Snodderly, P.K. Brown, F.C. Delori, J.D. Auran The macular pigment I. Absorbance spectra, localization, and discrimination from other yellow pigments in primate retina Invest Ophthalmol Vis Sci 25 1984 660 673
17. A. Bindewald, A.C. Bird, S.S. Dandekar Classification of fundus autofluorescence patterns in early age-related macular disease Invest Ophthalmol Vis Sci 46 2005 3309 3314
18. J.R. Sparrow, K.D. Yoon, Y. Wu, K. Yamamoto Interpretations of fundus autofluorescence from studies of the bisretinoids of the retina Invest Ophthalmol Vis Sci 51 2010 4351 4357
19. R. Spaide Autofluorescence from the outer retina and subretinal space: hypothesis and review Retina 28 2008 5 35
20. P. Hahn, A.H. Milam, J.L. Dunaief Maculas affected by age-related macular degeneration contain increased chelatable iron in the retinal pigment epithelium and Bruch's membrane Arch Ophthalmol 121 2003 1099 1105
21. R.W. Wong, D.C. Richa, P. Hahn Iron toxicity as a potential factor in AMD Retina 27 2007 997 1003
22. J.L. Dunaief Iron induced oxidative damage as a potential factor in age-related macular degeneration: the Cogan Lecture Invest Ophthalmol Vis Sci 47 2006 4660 4664
23. A. Klettner, S. Koinzer, V. Waetzig Deferoxamine mesylate is toxic for retinal pigment epithelium cells in vitro, and its toxicity is mediated by p38 Cutan Ocul Toxicol 29 2010 122 129
24. A. Cases, J. Kelly, F. Sabater Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine Nephron 56 1990 19 23
25. M. Ravelli, P. Scaroni, S. Mombelloni Acute visual disorders in patients on regular dialysis given desferrioxamine as a test Nephrol Dial Transplant 5 1990 945 949
26. J. Pengloan, J. Dantal, C. Rossazza Ocular toxicity after a single intravenous dose of desferrioxamine in 2 hemodialyzed patients [letter] Nephron 46 1987 211 212
27. C. Bene, A. Manzler, D. Bene, G. Kranias Irreversible ocular toxicity from single "challenge" dose of deferoxamine Clin Nephrol 31 1989 45 48
28. N.F. Olivieri, J.R. Buncic, E. Chew Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions N Engl J Med 314 1986 869 873
29. A. Cohen, M. Martin, J. Mizanin Vision and hearing during deferoxamine therapy J Pediatr 117 1990 326 330
30. S.H. Chen, D.C. Liang, H.C. Lin Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients J Pediatr Hematol Oncol 27 2005 651 653